Abstract
Histamine is a biogenic amine synthesized by the enzymatic decarboxylation of histidine. Implication of histamine in allergy is well described but histamine is also found in some specific neurones, functions as a neurotransmitter and regulates sleep/wake cycles, hormonal secretion, cardiovascular control and thermo-regulation. We have developed a TR-FRET histamine assay, based on the competition between sample histamine and allophycocyanine (XL665) labelled histamine for binding to a Europium cryptate (EuK) labelled antibody. As histamine is a small monoamine molecule, high affinity antibodies have been raised against carrier protein conjugated histamine. Therefore, sample histamine needs to be derivatized in the same way as the conjugated histamine, so that the antibody will have a similar affinity for both molecules. This acylation step is performed directly in wells and does not need to be done in separate vials, making handling easier for large numbers of samples. The incubation takes place at room temperature for 3 hours. The assay covers a measurement range of 1.56 to 400 nM and shows an analytical sensitivity of 1.3nM. We have shown that miniaturization of sample and reagents volumes down to 20μl does not alter these performances. This histamine release assay provides a particularly well adapted procedure for HTS and secondary screening compared to current heterogeneous methods.
Keywords: Homogeneous assay, homogeneous time resolved fluorescence, europium cryptate, histamine
Combinatorial Chemistry & High Throughput Screening
Title: Homogeneous Time Resolved Fluorescence Assay to Measure Histamine Release
Volume: 6 Issue: 8
Author(s): Emmanuel J. Claret, Josy Ouled-Diaf and Patrick Seguin
Affiliation:
Keywords: Homogeneous assay, homogeneous time resolved fluorescence, europium cryptate, histamine
Abstract: Histamine is a biogenic amine synthesized by the enzymatic decarboxylation of histidine. Implication of histamine in allergy is well described but histamine is also found in some specific neurones, functions as a neurotransmitter and regulates sleep/wake cycles, hormonal secretion, cardiovascular control and thermo-regulation. We have developed a TR-FRET histamine assay, based on the competition between sample histamine and allophycocyanine (XL665) labelled histamine for binding to a Europium cryptate (EuK) labelled antibody. As histamine is a small monoamine molecule, high affinity antibodies have been raised against carrier protein conjugated histamine. Therefore, sample histamine needs to be derivatized in the same way as the conjugated histamine, so that the antibody will have a similar affinity for both molecules. This acylation step is performed directly in wells and does not need to be done in separate vials, making handling easier for large numbers of samples. The incubation takes place at room temperature for 3 hours. The assay covers a measurement range of 1.56 to 400 nM and shows an analytical sensitivity of 1.3nM. We have shown that miniaturization of sample and reagents volumes down to 20μl does not alter these performances. This histamine release assay provides a particularly well adapted procedure for HTS and secondary screening compared to current heterogeneous methods.
Export Options
About this article
Cite this article as:
Claret J. Emmanuel, Ouled-Diaf Josy and Seguin Patrick, Homogeneous Time Resolved Fluorescence Assay to Measure Histamine Release, Combinatorial Chemistry & High Throughput Screening 2003; 6 (8) . https://dx.doi.org/10.2174/138620703771826892
DOI https://dx.doi.org/10.2174/138620703771826892 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Giardiasis: An Overview
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Editorial Board Member
Current Stem Cell Research & Therapy Editorial (Thematic Issue: Novel Inflammatory Biomarkers in Cardiovascular Disease: From Molecular Mechanisms to Therapeutic Targets (Part-II))
Current Medicinal Chemistry Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design Interferons Mediate Antiviral Immunity with Special Reference to Influenza Virus
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Mechanical Stimulation Protocols of Human Derived Cells in Articular Cartilage Tissue Engineering – A Systematic Review
Current Stem Cell Research & Therapy Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Brain-to-Plasma Distribution Ratio of the Biflavone Amentoflavone in the Mouse
Drug Metabolism Letters Diagnostic Value of Assessment of Serum Cortisol, Hepcidin and Thyroid Hormones Levels in Neonates with Late-Onset Sepsis
Infectious Disorders - Drug Targets Neutrophil Derived Microvesicles: Emerging Role of a Key Mediator to the Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin Delivery Systems for Controlling Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Impact of Immunosuppressive Drugs on the Analysis of T-Cell Activation
Current Medicinal Chemistry Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Beyond Cox-Inhibition: ‘Side-Effects’ of Ibuprofen on Neoplastic Development and Progression
Current Pharmaceutical Design Follicular Immunology Environment and the Influence on In Vitro Fertilization Outcome
Current Women`s Health Reviews Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Development of an Insect Cell-Free System
Current Pharmaceutical Biotechnology Metabolic Analysis of Triptolide Microspheres in Human, Dog, Rabbit and Rat Liver Microsomes with UPLC-MS/MS Method
Current Pharmaceutical Analysis The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine
Current Molecular Medicine Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design